Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX
Other stock markets
 15:16:22 2024-04-29 EDT 		5-day change 1st Jan Change
25.2 USD +1.27% Intraday chart for BridgeBio Pharma, Inc. +0.50% -37.59%
04-07 BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement CI
03-20 JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BridgeBio Pharma : BBIO – BBO-8520 – 2024 AACR – Rapid and Complete Blockade of Effector Binding Results
PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy
AQ
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AQ
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement
CI
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GL
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating
MT
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating
MT
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing
PU
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating
MT
BridgeBio Pharma Prices $250 Million Stock Offering
MT
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
GL
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
BridgeBio Pharma Commences $250 Million Share Offering
MT
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
GL
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating
MT
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million
MT
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GL
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. News BridgeBio Pharma, Inc.